19 results
8-K
EX-99.1
KA
Kineta Inc
3 Oct 19
Regulation FD Disclosure
8:01am
Combination Study Demographics *Lung Colonization status associated with a more rapid decline in pulmonary status (e.g., Burkholderia cenocepacia … affect the baseline demographics and disease burden of subjects enrolled in CF clinical trials
Ongoing Phase 2 Study with Double and Triple Combination
8-K
EX-99.1
KA
Kineta Inc
4 Dec 19
Regulation FD Disclosure
8:10am
2 2 Double and Triple Combination Study Demographics *Lung Colonization status associated with a more rapid decline in pulmonary status (e.g … modulator therapy would affect the baseline demographics and disease burden of subjects enrolled in CF clinical trials
Ongoing Phase 2 Study
8-K
EX-99.1
KA
Kineta Inc
5 Aug 19
Regulation FD Disclosure
5:20pm
(4.2) 19.9 (2.2) 22.2 (2.1) 22.3 (0.9) 22.7 (2.3) Subjects with lung colonization status* 1 2 2 0 0 1 Double and Triple Combination Study Demographics
8-K
EX-99.1
KA
Kineta Inc
1 Nov 19
Regulation FD Disclosure
8:00am
Demographics *Lung Colonization status associated with a more rapid decline in pulmonary status (e.g., Burkholderia cenocepacia and Mycobacterium abscessus
8-K/A
EX-99.1
KA
Kineta Inc
13 May 19
Departure of Directors or Certain Officers
5:28pm
0 1 Double and Triple Combination Study Demographics 9 PTI public disclosures on October 17, 2018 and March 25, 2019
Triple combination Double
8-K
EX-99.1
at3k7l2
13 May 19
Departure of Directors or Certain Officers
8:00am
8-K
EX-99.2
dfgiqpu2fu8de5
17 Dec 19
Proteostasis Therapeutics Announces Positive Phase 2 Topline Results from Proprietary CFTR
8:30am
8-K
EX-99.2
ixtnei
22 Jan 20
Proteostasis Therapeutics Announces Keystone Symposia Presentation of
7:00am
8-K
EX-99.1
c4037yoa1j
5 Mar 20
Regulation FD Disclosure
4:30pm
8-K
EX-99.1
1rzcmk
10 Nov 21
Regulation FD Disclosure
7:12am
8-K
EX-99.1
nrbcjh5712lq
28 Nov 18
Regulation FD Disclosure
8:00am
8-K
EX-99.2
2co0z5y iog05s0h
17 Oct 18
Proteostasis Therapeutics Announces Positive Preliminary Results from
4:30pm
8-K
EX-99.2
fgoohz052x7ok3zmt
6 Jun 18
Proteostasis Announces Positive Data from Ongoing Phase 1 Study ofPTI-801 in Cystic Fibrosis Patients on Background Orkambi® Therapy
4:11pm
8-K
EX-99.1
is7gnk6n8wf60s 6m
7 Jan 19
Departure of Directors or Certain Officers
7:31am
8-K
EX-99.1
tenye0ibu2 pm
5 Jan 24
Regulation FD Disclosure
4:30pm
8-K
EX-99.2
cjzonola0nnn
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-99.1
5one4ephn16 rffs
3 Oct 18
Regulation FD Disclosure
8:01am
8-K
EX-99.2
szkhd3cyxh2k8r
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
EX-99.1
i26w58jwuqc2hu
26 Jul 18
Regulation FD Disclosure
7:59am
- Prev
- 1
- Next